Pharma Power Japan Barely In COVID Vaccines Race. Why?
Long-Standing Lag In New Spotlight
Executive Summary
Despite having multiple world-class pharma companies and innovative research, Japan is notably absent as a source of candidate vaccines for the coronavirus. The pandemic is again throwing into sharp relief past and present challenges around the country's vaccines sector.
You may also be interested in...
Japan Pricing Environment ‘Highly Unpredictable’: PhRMA
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the past week's major events in the global biopharma industry, as brought to you by Scrip's global team, in this mini podcast version of Five Must-Know Things.